Advertisement
Screener

Immunocore Holdings plc (IMCR) Capital Expenditures Incurred but Not yet Paid

2.1 / 5 stars · 15/35 Roast Me

Immunocore Holdings plc Capital Expenditures Incurred but Not yet Paid

Immunocore Holdings plc (IMCR) reported Capital Expenditures Incurred but Not yet Paid of $216.00 thousand for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-06.

Financial Statements › Cash Flow › Other Cash Flow Items

us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2025-11-06

  • 2025-09-30: Capital Expenditures Incurred but Not yet Paid 9 month $216.00K.
  • 2024-09-30: Capital Expenditures Incurred but Not yet Paid 9 month $840.00K.
Period endCapital Expenditures Incurred but Not yet Paid 9 month
2025-09-30$216.00K
10-Q · filed 2025-11-06
2024-09-30$840.00K
10-Q · filed 2025-11-06

Similar stocks

Stock NameCountryMarket CapPE Ratio
Taysha Gene Therapies, Inc. (TSHA)United States$1.564B-14.80
Hemab Therapeutics Holdings, Inc. (COAG)United States$1.672B
NOVAVAX INC (NVAX)United States$1.748B-6.26
Inhibrx Biosciences, Inc. (INBX)United States$1.477B-10.08
Maze Therapeutics, Inc. (MAZE)United States$1.457B-12.40
Vir Biotechnology, Inc. (VIR)United States$1.814B-6.85
Vericel Corp (VCEL)United States$2.011B93.97
Replimune Group, Inc. (REPL)United States$1.186B-3.13
RECURSION PHARMACEUTICALS, INC. (RXRX)United States$2.080B-3.78
Kodiak Sciences Inc. (KOD)United States$2.090B-10.12